27th Jun 2016 08:16
LONDON (Alliance News) - Akers Biosciences Inc on Monday said it has signed its first distribution agreement for BreathScan OxiChek with a division of Cardinal Health, a Fortune 500 health care services organisation.
Akers signed the deal, for the US market, with Aero-Med for OxiChek, which it said is the first disposable breath test to rapidly determine levels of oxidative stress in the body by measuring the levels of certain abundant free radicals. The product was developed as part of the Akers Wellness line.
"Frequent use of OxiChek may help health practitioners to monitor and adjust their clients' regimen of nutritional supplementation in order to manage oxidative stress - an indicator of the overall health and wellbeing of a person," said Akers.
OxiChek works with BreathScan Lync, the new bluetooth-enabled reading device from Akers Wellness, to enable users to monitor oxidative stress via a mobile device.
"Aero-Med is targeting the large specific markets in the United States of anti-aging, functional and integrative health and wellness treatment practitioners and has already placed orders for OxiChek. OxiChek will be initially represented by an Aero-Med sales team focusing on the six New England states both through direct sales and, in due course, through an e-commerce platform under development," said the company.
Akers plans to appoint further partners for OxiChek with distribution capabilities within other target markets, including chiropractors and multi-level marketing organisations, it said.
Akers shares were untraded on Monday morning, last trading at 140.10 pence per share.
By Joshua Warner; [email protected]; @JoshAlliance
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
AKR.L